Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

Background In pancreatic ductal adenocarcinoma (PDAC), the chemokine (C-C motif) ligand 2 (CCL2)/chemokine (C-C motif) receptor 2 (CCR2) axis plays a key role in immunosuppressive properties of the tumor microenvironment, patient prognosis, and chemoresistance. This phase Ib study assessed the effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Noel, Marcus, O’Reilly, Eileen M., Wolpin, Brian M., Ryan, David P., Bullock, Andrea J., Britten, Carolyn D., Linehan, David C., Belt, Brian A., Gamelin, Eric C., Ganguly, Bishu, Yin, Donghua, Joh, Tenshang, Jacobs, Ira A., Taylor, Carrie T., Lowery, Maeve A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211198/
https://www.ncbi.nlm.nih.gov/pubmed/31297636
http://dx.doi.org/10.1007/s10637-019-00830-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211198/
https://www.ncbi.nlm.nih.gov/pubmed/31297636
http://dx.doi.org/10.1007/s10637-019-00830-3

Ejemplares similares